Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

Melanie Schroeder,1 Nicole Benjamin,2 Laura Atienza,3 Chandroday Biswas,4 Alan Martin,5 John D Whalen,6 José Luis Izquierdo Alonso,7 Juan Antonio Riesco Miranda,8 Juan José Soler-Cataluña,9 Alicia Huerta,3 Afisi S Ismaila10,11 1Value Evidence and Outcomes, GlaxoSmith...

Full description

Bibliographic Details
Main Authors:	Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, Izquierdo Alonso JL, Riesco Miranda JA, Soler-Cataluña JJ, Huerta A, Ismaila AS
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-07-01
Series:	International Journal of COPD
Subjects:	cost-utility analysis health-related quality of life incremental cost-effectiveness ratio fluticasone furoate vilanterol umeclidinium
Online Access:	https://www.dovepress.com/cost-effectiveness-analysis-of-a-once-daily-single-inhaler-triple-ther-peer-reviewed-article-COPD

Similar Items

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01)

The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice
by: V. V. Naumova, et al.
Published: (2022-04-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01)

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China
by: Lan Y, et al.
Published: (2022-03-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
by: Sethi S, et al.
Published: (2023-04-01)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
by: Shukla S, et al.
Published: (2021-11-01)

Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma
by: Akira Umeda, et al.
Published: (2019-01-01)

Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease
by: Elena V. Bolotova, et al.
Published: (2022-03-01)

Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
by: Wilson MR, et al.
Published: (2017-03-01)

Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review
by: A. A. Viesel, et al.
Published: (2022-01-01)

In Vitro Analysis of Nine MicroRNAs in CD8+ T Cells of Asthmatic Patients and the Effects of Two FDA-approved Drugs
by: Mohsen Badalzadeh, et al.
Published: (2019-08-01)

Increased treatment adherence in patients with chronic obstructive pulmonary disease when using a fixed triple combination
by: E. V. Bolotova, et al.
Published: (2021-10-01)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01)

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
by: Vallejo-Aparicio LA, et al.
Published: (2018-09-01)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01)

New possibilities of pharmacotherapy for chronic obstructive pulmonary disease
by: A. I. Sinopalnikov, et al.
Published: (2018-10-01)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
by: Kerwin EM, et al.
Published: (2017-02-01)

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
by: Roberto W. Dal Negro, et al.
Published: (2018-06-01)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
by: Ami R. Buikema, et al.
Published: (2018-10-01)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
by: Kardos P, et al.
Published: (2016-11-01)

Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
by: Daniel Dedman, et al.
Published: (2019-04-01)

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD
by: Siler TM, et al.
Published: (2016-05-01)

Combined therapy with inhaled glucocorticosteroids and long-acting β2-agonists in patients with bronchial asthma: the problem of choice
by: A. I. Sinopalnikov
Published: (2021-10-01)

In vitro Antibacterial Activity of Mometasone Furoate, Fluticasone Propionate and Fluticasone Furoate Nasal Preparations Against Streptococcus pneumoniae, Hemophilus influenzae, Streptococcus viridans, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli
by: Philip Lance A. Liu, et al.
Published: (2010-06-01)

COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
by: N. L. Pogudina, et al.
Published: (2017-08-01)

A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
by: Philippe Bareille, et al.
Published: (2020-02-01)

Current optimization of combined therapy for chronic obstructive pulmonary disease
by: E N Popova
Published: (2015-12-01)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Wei-Chun Huang, et al.
Published: (2022-12-01)

Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging
by: Omar Usmani, et al.
Published: (2023-09-01)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
by: Woodcock Ashley, et al.
Published: (2011-12-01)

Comparison of Fluticasone Furoate Nasal Spray Versus Combined Oral Anti-Histamine and Anti-Leukotriene Therapy in Allergic Rhinitis
by: Junaid Shahzad, et al.
Published: (2018-06-01)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
by: Maria Doulaptsi, et al.
Published: (2021-09-01)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
by: Masato Muraki, et al.
Published: (2021-01-01)

A comparative study of fluticasone propionate, mometasone furoate, and saline nasal spray in the treatment of children with adenoid hypertrophy}
by: Gurbax Singh, et al.
Published: (2023-01-01)

Comparative study of the efficacy and safety of intranasal azelastine hydrochloride and fluticasone furoate in the treatment of allergic rhinitis
by: Nandish Chennakeshavaraju, et al.
Published: (2020-01-01)

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
by: Paly VF, et al.
Published: (2022-12-01)

Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
by: Bollmeier SG, et al.
Published: (2016-05-01)

Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy
by: Bogart M, et al.
Published: (2024-02-01)

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study
by: Requena G, et al.
Published: (2021-03-01)